19-Dec-2025
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
TipRanks (Fri, 19-Dec 5:09 PM ET)
Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025
Globe Newswire (Fri, 12-Dec 7:00 AM ET)
Globe Newswire (Mon, 8-Dec 6:50 AM ET)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Wed, 3-Dec 4:01 PM ET)
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Globe Newswire (Mon, 1-Dec 7:00 AM ET)
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Mon, 3-Nov 4:01 PM ET)
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
Globe Newswire (Mon, 3-Nov 9:08 AM ET)
Globe Newswire (Mon, 3-Nov 9:08 AM ET)
Syndax Announces Participation in November Investor Conferences
Globe Newswire (Thu, 30-Oct 7:00 AM ET)
Market Chameleon (Mon, 27-Oct 3:15 AM ET)
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Syndax Pharmaceuticals trades on the NASDAQ stock market under the symbol SNDX.
As of December 19, 2025, SNDX stock price climbed to $20.77 with 2,074,209 million shares trading.
SNDX has a beta of 0.98, meaning it tends to be less sensitive to market movements. SNDX has a correlation of 0.06 to the broad based SPY ETF.
SNDX has a market cap of $1.81 billion. This is considered a Small Cap stock.
Last quarter Syndax Pharmaceuticals reported $46 million in Revenue and -$.70 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.02.
In the last 3 years, SNDX traded as high as $29.86 and as low as $8.58.
The top ETF exchange traded funds that SNDX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
SNDX has outperformed the market in the last year with a price return of +61.6% while the SPY ETF gained +18.1%. SNDX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +40.5% and +2.2%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
SNDX support price is $19.51 and resistance is $20.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNDX shares will trade within this expected range on the day.